Search

Your search keyword '"Chiusa L"' showing total 262 results
Start Over Author "Chiusa L"
262 results on '"Chiusa L"'

3. Pathological non-response to chemotherapy in a neoadjuvant setting of breast cancer: an inter-institutional study

Author

Balmativola, D., Marchiò, C., Maule, M., Chiusa, L., Annaratone, L., Maletta, F., Montemurro, F., Kulka, J., Figueiredo, P., Varga, Z., Liepniece-Karele, I., Cserni, G., Arkoumani, E., Amendoeira, I., Callagy, G., Reiner-Concin, A., Cordoba, A., Bianchi, S., Decker, T., Gläser, D., Focke, C., van Diest, P., Grabau, D., Lips, E., Wesseling, J., Arisio, R., Medico, E., Wells, C., and Sapino, A.

Published
2014
Full Text
View/download PDF

28. Cell cycle and viral and immunologic profiles of head and neck squamous cell carcinoma as predictable variables of tumor progression. M. DE ANDREA CO-FIRST AUTHOR

Author

Rittà, M, DE ANDREA, Marco, Mondini, M, Mazibrada, Jasenka, Giordano, Carlo, Pecorari, Giancarlo, Garzaro, Massimiliano, Landolfo, Vincenzo, Schena, M, Chiusa, L, and Landolfo, Santo Giuseppe

Subjects
p53, head and neck squamous cell carcinoma, human papillomavirus, proliferation index, macrophage infiltration
Published
2009

31. Prognostic value of quantitative analysis of WT1 gene transcripts in adult acute lymphoblastic leukemia

Author

Chiusa, L., Di Celle, P. F., Campisi, P., Ceretto, C., Marmont, F., and achille PICH

Subjects
Adult, Male, adult acute lymphoblastic leukemia, quantitative WT1 expression, prognosis, Adolescent, Middle Aged, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Prognosis, Predictive Value of Tests, Humans, Female, RNA, Messenger, WT1 Proteins, Aged
Abstract

We quantified Wilm's tumor gene (WT1) using a real time quantitative polymerase chain reaction in 20 adult patients with acute lymphoblastic leukemia at presentation. A WT1 level greater than 906 (median value for the whole series) was a significant predictor of a poor disease-free and overall survival in uni- and multivariate analyses.

Published
2006

38. Inter- and intratumoral heterogeneity of BCL2 correlates with IgH expression and prognosis in follicular lymphoma

Author

Barreca, A, Martinengo, C, Annaratone, L, Righi, L, Chiappella, A, Ladetto, M, Demurtas, A, Chiusa, L, Stacchini, A, Crosetto, N, van Oudenaarden, A, Chiarle, R, Barreca, A, Martinengo, C, Annaratone, L, Righi, L, Chiappella, A, Ladetto, M, Demurtas, A, Chiusa, L, Stacchini, A, Crosetto, N, van Oudenaarden, A, and Chiarle, R

Abstract

Most follicular lymphomas (FLs) are genetically defined by the t(14;18)(q32;q21) translocation that juxtaposes the BCL2 gene to the immunoglobulin heavy chain (IgH) 3' regulatory regions (IgH-3'RRs). Despite this recurrent translocation, FL cases are heterogeneous in terms of intratumoral clonal diversity for acquired mutations and variations in the tumor microenvironment. Here we describe an additional mechanism that contributes to inter- and intratumoral heterogeneity in FLs. By applying a novel single-molecule RNA fluorescence-based in situ hybridization (FISH) technique to detect mRNA molecules of BCL2 and IgH in single cells, we found marked heterogeneity in the number of BCL2 mRNA transcripts within individual lymphoma cells. Moreover, BCL2 mRNA molecules correlated with IgH mRNA molecules in individual cells both in t(14;18) lymphoma cell lines and in patient samples. Consistently, a strong correlation between BCL2 and IgH protein levels was found in a series of 205 primary FL cases by flow cytometry and immunohistochemistry. Inter- and intratumoral heterogeneity of BCL2 expression determined resistance to drugs commonly used in FL treatment and affected overall survival of FL patients. These data demonstrate that BCL2 and IgH expressions are heterogeneous and coregulated in t(14;18)-translocated cells, and determine the response to therapy in FL patients.

Published
2014

48. Castleman's disease

Author

Palestro, G, Turrini, Francesco Michelangelo, Pagano, M, and Chiusa, L.

Subjects
Hyalin, Interleukin-6, Castleman Disease, Herpesvirus 8, Human, Plasma Cells, Mediastinal Diseases, Blood Vessels, Humans, Lymph Nodes
Abstract

Castleman's disease (CD) is a rare atypical lymphoproliferative disorder whose morphology, soon after the original presentation of Castleman et al., has been definitely subdivided in a hyaline vascular (HV) and plasma cell (PC) histopathological pattern, with intermediate variants. The former occurs much more frequently than the latter and is usually localized to the mediastinum or pulmonary hilum. The latter involves lymph nodes separately or in aggregations and often displays multicentricity with systemic symptoms including autoimmune phenomena and aggressive course. Infections are the most frequent causes of patient demise in these cases, followed by malignancies such as Kaposi's sarcoma, malignant lymphoma or epithelial neoplasia. Increase of follicular dendritic reticulum cells (FDRC), often dysplastic, in the germinal center (GC) and marginal zone (MZ), broad MZ expansion with prominence of immunophenotypically aberrant B cells (Ki B3-negative, CD5-positive), possible predominance of paracortical plasma cells often with clusters of clonal l-light chain restricted plasma cells, increase of paracortical plasmacytoid monocytes, represent common hallmarks of CD. However, small hyalinized and hypervascular GCs with hypervascular interfollicular stroma and sinus effacement are common features of the HV variant, whereas hyperplastic GCs with plasma cell aggregates in lymph node paracortex and partially spared sinuses are characteristic features of the PC variant. The frequent concomitance of the HV and PC types at separate sites, together with transient morphological patterns from one type to the other and from the localized to multicentric form during the course of the disease, along with B and T cell impaired functions, with frequent development of autoantibodies, have suggested that CD is a single disorder related to immune dysregulation. A key event in the pathogenesis of CD has been recently suggested to be an abnormal production of a B cell growth factor, such as IL-6, leading to lymphoproliferation and plasma cell differentiation and being involved in the oncogenesis of plasmacytoma. In this event, Kaposi's sarcoma associated virus (HHV-8), which has been found in many cases of CD, especially in the multicentric form, could play a crucial role both in producing IL-6 and releasing angiogenic factors. A possible differentiation block may lead to the development of a malignant lymphoma. Kaposi's sarcoma or other malignant neoplasias can be supposed to be consequences of the immunodeficiency typical of CD.

Published
2000

Catalog

Books, media, physical & digital resources
See catalog results